OBJECTIVES: Population-based sequencing of primary/recent HIV infections (PHIs) can provide a framework for understanding transmission dynamics of local epidemics. In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance. METHODS: HIV-1 pol sequence datasets were available for all genotyped PHI (<6 months postseroconversion; n = 848 subtype B infections, 1997-2007). Phylogenetic analysis established clustered transmission events, based on maximum likelihood topologies having high bootstrap values (>98%) and short genetic distances. The distributions of resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors in unique and clustered transmissions were ascertained. RESULTS: Episodic clustering was observed in half of recent/early stage infections from 1997-2008. Overall, 29 and 28% of new infections segregated into small (<5 PHI/cluster, n = 242/848) and large transmission chains (> or =5 PHI/cluster, n = 239/848), averaging 2.8 +/- 0.1 and 10.3 +/- 1.0 PHI/cluster, respectively. The transmission of nucleoside analogue mutations and 215 resistant variants (T215C/D/I/F/N/S/Y) declined with clustering (7.9 vs. 3.4 vs. 1.2 and 5.8 vs. 1.7 vs. 1.1% for unique, small, and large clustered transmissions, respectively). In contrast, clustering was associated with the increased transmission of viruses harbouring resistance to nonnucleoside reverse transcriptase inhibitors (6.6 vs. 6.0 vs. 15.5%, respectively). CONCLUSION: Clustering in early/PHI stage infection differentially affects transmission of drug resistance to different drug classes. Public health, prevention and diagnostic strategies, targeting PHI, afford a unique opportunity to curb the spread of transmitted drug resistance.
OBJECTIVES: Population-based sequencing of primary/recent HIV infections (PHIs) can provide a framework for understanding transmission dynamics of local epidemics. In Quebec, half of PHIs represent clustered transmission events. This study ascertained the cumulative implications of clustering on onward transmission of drug resistance. METHODS:HIV-1 pol sequence datasets were available for all genotyped PHI (<6 months postseroconversion; n = 848 subtype B infections, 1997-2007). Phylogenetic analysis established clustered transmission events, based on maximum likelihood topologies having high bootstrap values (>98%) and short genetic distances. The distributions of resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors and protease inhibitors in unique and clustered transmissions were ascertained. RESULTS:Episodic clustering was observed in half of recent/early stage infections from 1997-2008. Overall, 29 and 28% of new infections segregated into small (<5 PHI/cluster, n = 242/848) and large transmission chains (> or =5 PHI/cluster, n = 239/848), averaging 2.8 +/- 0.1 and 10.3 +/- 1.0 PHI/cluster, respectively. The transmission of nucleoside analogue mutations and 215 resistant variants (T215C/D/I/F/N/S/Y) declined with clustering (7.9 vs. 3.4 vs. 1.2 and 5.8 vs. 1.7 vs. 1.1% for unique, small, and large clustered transmissions, respectively). In contrast, clustering was associated with the increased transmission of viruses harbouring resistance to nonnucleoside reverse transcriptase inhibitors (6.6 vs. 6.0 vs. 15.5%, respectively). CONCLUSION: Clustering in early/PHI stage infection differentially affects transmission of drug resistance to different drug classes. Public health, prevention and diagnostic strategies, targeting PHI, afford a unique opportunity to curb the spread of transmitted drug resistance.
Authors: H Salomon; M A Wainberg; B Brenner; Y Quan; D Rouleau; P Coté; R LeBlanc; E Lefebvre; B Spira; C Tsoukas; R P Sekaly; B Conway; D Mayers; J P Routy Journal: AIDS Date: 2000-01-28 Impact factor: 4.177
Authors: Jean-Pierre Routy; Nimâ Machouf; Michael D Edwardes; Bluma G Brenner; Réjean Thomas; Benoit Trottier; Danielle Rouleau; Cécile L Tremblay; Pierre Côté; Jean-Guy Baril; Robert S Remis; Rafick P Sékaly; Mark A Wainberg Journal: AIDS Date: 2004-11-19 Impact factor: 4.177
Authors: J S Koopman; J A Jacquez; G W Welch; C P Simon; B Foxman; S M Pollock; D Barth-Jones; A L Adams; K Lange Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1997-03-01
Authors: Martin S Hirsch; Huldrych F Günthard; Jonathan M Schapiro; Françoise Brun-Vézinet; Bonaventura Clotet; Scott M Hammer; Victoria A Johnson; Daniel R Kuritzkes; John W Mellors; Deenan Pillay; Patrick G Yeni; Donna M Jacobsen; Douglas D Richman Journal: Clin Infect Dis Date: 2008-07-15 Impact factor: 9.079
Authors: Glenn Lawyer; Eugen Schülter; Rolf Kaiser; Stefan Reuter; Mark Oette; Thomas Lengauer Journal: Med Microbiol Immunol Date: 2012-01-20 Impact factor: 3.402
Authors: Philip A Chan; Shahzeb Kazi; Amaad Rana; Ilyse Blazar; Colette C Dejong; Kenneth H Mayer; Thomas K Huard; Kim Carleton; Fizza Gillani; Nicole Alexander; Zoanne Parillo; Timothy P Flanigan; Rami Kantor Journal: AIDS Res Hum Retroviruses Date: 2012-07-25 Impact factor: 2.205
Authors: Ethan Morgan; Britt Skaathun; Georgios K Nikolopoulos; Dimitrios Paraskevis; Leslie D Williams; Pavlo Smyrnov; Samuel R Friedman; John A Schneider Journal: AIDS Behav Date: 2019-01
Authors: Bluma G Brenner; Michel Roger; David Stephens; Daniela Moisi; Isabelle Hardy; Jonathan Weinberg; Reuven Turgel; Hugues Charest; James Koopman; Mark A Wainberg Journal: J Infect Dis Date: 2011-10-01 Impact factor: 5.226
Authors: Vlad Novitsky; Melissa Zahralban-Steele; Mary Fran McLane; Sikhulile Moyo; Erik van Widenfelt; Simani Gaseitsiwe; Joseph Makhema; M Essex Journal: J Clin Microbiol Date: 2015-06-03 Impact factor: 5.948
Authors: Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis Journal: PLoS One Date: 2010-06-08 Impact factor: 3.240